<DOC>
	<DOCNO>NCT01518556</DOCNO>
	<brief_summary>The purpose study determine whether idarubicin dose intensification safe effective remission induction therapy acute myeloid leukemia .</brief_summary>
	<brief_title>Safety Efficacy Study Idarubicin Dose Intensification Treat Acute Myeloid Leukemia</brief_title>
	<detailed_description>Up nowadays , standard induction therapy acute myeloid leukemia ( AML ) consist cytarabine 100-200 mg per square meter body surface area ( BSA ) per day continuous infusion 7 day idarubicin 12 mg per square meter daunorubicin 45 mg per square meter BSA per day 3 day . This standard therapy induces complete remission ( CR ) 50-75 % young adult 40-50 % old adult . Recently two cooperative group prospectively compare 45 mg per square meter daunorubicin 90 mg per square meter BSA . They report high-dose daunorubicin , compare standard dose one , result significantly high CR rate improve overall survival ( OS ) age 65 without additional toxic effect . Daunorubicin commonly use anthracycline ; however , idarubicin longer intracellular retention time show rapid clearance marrow blast . In early 1990 , three prospectively randomized study show combined regimen idarubicin cytarabine superior one daunorubicin cytarabine induction therapy AML adult . When compare daunorubicin 45-50 mg per square meter idarubicin 12-13 mg per square meter induction therapy , significant difference hematologic non-hematologic toxicity , include cardiac toxicity . Phase I study idarubicin patient acute leukemia chronic myelogenous leukemia blast crisis report dose-limiting toxicity ( DLT ) stomatitis anorexia maximum tolerate dose ( MTD ) 15 mg per square meter BSA per day 3 day . Based result study , investigator generally administer idarubicin 12 mg per square meter per day 3 day remission induction therapy AML . Meanwhile Sanz et al . administer idarubicin 12 mg per square meter per day 4 day patient acute promyelocytic leukemia , Tedeschi et al . do single high-dose idarubicin 40 mg per square meter combine high-dose cytarabine 3 g per square meter per day 5 day patient acute lymphoblastic leukemia , significant increase severe toxicity . The MTD idarubicin reevaluate treatment acute leukemia , especially era granulocyte colony-stimulating factor well supportive care available . In phase I study , idarubicin 12 mg per square meter BSA per day 3 day give three patient first stage idarubicin dose increase 3 mg per square meter BSA stage . The phase I study consist 3 stage idarubicin dose increase 18 mg per square meter BSA per day 3 day unless DLTs develop 33 % enrolled patient stage . In subsequent phase II study , MTD determine phase I study 18 mg per square meter idarubicin give enrol patient . There three large study enrol total 942 previously untreated adult patient AML idarubicin 12-13 mg per square meter BSA per day 3 day cytarabine 100 mg per square meter daily 7 day administer intravenously . Therefore , investigator adopt historical control group term statistical assessment . In conclusion , investigator desire determine safety effectiveness intensify dose idarubicin treatment acute myeloid leukemia phase I II study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Patient fully inform , complete understand fo study , give voluntary write informed consent comply protocol requirement . previously untreated de novo secondary acute myeloid leukemia , include biphenotypic leukemia age 20 65 year adequate organ function , unless abnormality attributable leukemia leave ventricular ejection fraction &gt; 45 % serum creatinine &lt; 1.5 x upper limit normal total bilirubin &lt; 1.5 x upper limit normal alanine transferase aspartate transferase &lt; 2.5 x upper limit normal liver function abnormality attributable underlying leukemia , ALT AST &lt; 5 x upper limit normal Eastern Cooperative Oncology Group performance status score 0 2 hypersensitivity study drug malignancy within 3 year , except cure nonmelanoma skin cancer curatively treat situ carcinoma cervix New York Heart Association class III IV heart failure , severe uncontrolled cardiac disease myocardial infarction within previous 6 month prior date consent incapable give voluntary write informed consent comply protocol requirement , result drug alcohol intoxication , neurological psychiatric disorder pregnant breastfeed recent chemotherapy within 4 week prior study treatment acute promyelocytic leukemia current recent treatment investigational medicinal product within 28 day prior study enrollment unsuitable study , investigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Idarubicin</keyword>
	<keyword>Remission Induction</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Survival</keyword>
</DOC>